Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. News
  7. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

JW Therapeutics Co. Ltd Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021

08/27/2021 | 09:00am EST

JW (Cayman) Therapeutics Co. Ltd. reported unaudited consolidated earnings results for the Six months ended June 30, 2021. For the period, the company reported operating loss of RMB 333,578,000 compared to RMB 158,311,000 a year ago. Loss for the period was RMB 280,695,000 compared to RMB 650,029,000 a year ago. Basic loss per share was RMB 0.71 compared to RMB 9.96 a year ago.


© S&P Capital IQ 2021
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
12/03JW Therapeutics Co. Ltd Announces Board and Committee Changes
CI
10/04JW CAYMAN THERAPEUTICS : Therapeutics Awards 7 Million Share Options, Nearly 5 Million Res..
MT
09/28JW (CAYMAN) THERAPEUTICS : to Start Clinical Trials of Multiple Myeloma Treatment in China
MT
09/27JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
CI
09/26JW CAYMAN THERAPEUTICS : Therapeutics Says Immunotherapy Shows Long-Term Efficacy in Large..
MT
09/26JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel ..
CI
09/06JW CAYMAN THERAPEUTICS : Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel..
AQ
09/03JW CAYMAN THERAPEUTICS : China Approves JW Therapeutics' Immunotherapy for Lymphoma Treatm..
MT
09/03JW Therapeutics Co. Ltd Announces NMPA Approval of Relmacabtagene Autoleucel Injection ..
CI
08/27JW Therapeutics Co. Ltd Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
More news
Financials
Sales 2021 103 M 16,1 M 16,1 M
Net income 2021 -629 M -98,7 M -98,7 M
Net cash 2021 1 897 M 298 M 298 M
P/E ratio 2021 -6,23x
Yield 2021 -
Capitalization 3 484 M 546 M 547 M
EV / Sales 2021 15,5x
EV / Sales 2022 3,83x
Nbr of Employees 477
Free-Float 56,1%
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,57 CNY
Average target price 24,58 CNY
Spread / Average Target 187%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Chi Shing Li Independent Non-Executive Director
Yiu Leung Cheung Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-60.23%546
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.21.78%65 758
VERTEX PHARMACEUTICALS-13.76%51 819